Drug Information

Drug General Information
Drug ID
D0O9PQ
Former ID
DNCL002131
Drug Name
AP26113
Drug Type
Small molecular drug
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 2 [524689], [542707]
Structure
Download
2D MOL

3D MOL
Formula
C26H34ClN6O2P
InChI
InChI=1S/C26H34ClN6O2P/c1-32(2)18-12-14-33(15-13-18)19-10-11-21(23(16-19)35-3)30-26-28-17-20(27)25(31-26)29-22-8-6-7-9-24(22)36(4,5)34/h6-11,16-18H,12-15H2,1-5H3,(H2,28,29,30,31)
InChIKey
OVDSPTSBIQCAIN-UHFFFAOYSA-N
PubChem Compound ID
57390074
PubChem Substance ID
136920266, 163557754, 163620756, 163686076, 185998864, 196372345, 208265498, 223366074, 223471428, 225848222, 237054225, 241177982, 249820313, 251910627, 252110336, 252214737, 252444133, 252470445
Target and Pathway
Target(s) ALK tyrosine kinase receptor Target Info Modulator [1572591]
KEGG Pathway Non-small cell lung cancer
WikiPathways Differentiation Pathway
References
Ref 524689ClinicalTrials.gov (NCT02094573) A Phase 2, Multicenter, Randomized Study of AP26113. U.S. National Institutes of Health.
Ref 542707(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7741).
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.